Avila Therapeutics Raises $30 Million, Signs Novartis Deal
Avila Therapeutics Inc., a Waltham, Mass.-based covalent drug development company, has raised $30 million in Series B funding. The Novartis Option Fund led the round, and was joined by return backers Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners. In related news, Avila has signed an option agreement with Novartis that could be worth a total of $200 million.
27 July 2009•4 mins read
